- Human pathology

Home > A. Molecular pathology > MET


MIM.164860 7q31 HGNC:7029

Tuesday 21 September 2004

c-met; MET protooncogene, HGFR, RCCP2, hepatocyte growth factor/scatter factor (HGF/SF) receptor; met proto-oncogene (hepatocyte growth factor receptor); HGFR, RCCP2; MET gene


- MET germline activating mutations in:

- MET somatic activating mutations in:

- MET amplification in :

- MET overexpression in :

  • MET-amplified gastric carcinoma (26404902)

Targeted therapy

Several c-MET targeting inhibitory molecules have already shown promising results in the treatment of patients with Non-small Cell Lung Cancer (NSCLC). Combination of EGFR- and c-MET-specific molecules may overcome EGFR tyrosine kinase inhibitor (TKI) resistance.

Neither expression of c-MET, nor the gene amplification status might be the best way to select patients for MET targeting therapies, since no correlation with the activation status of MET was observed. (26215852)

Open references

- Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Watermann I, Schmitt B, Stellmacher F, Müller J, Gaber R, Kugler Ch, Reinmuth N, Huber RM, Thomas M, Zabel P, Rabe KF, Jonigk D, Warth A, Vollmer E, Reck M, Goldmann T. Diagn Pathol. 2015 Jul 28;10:130. doi : 10.1186/s13000-015-0362-5 PMID: 26215852 (Free)


- Activating mutation in MET oncogene in familial colorectal cancer. Neklason DW, Done MW, Sargent NR, Schwartz AG, Anton-Culver H, Griffin CA, Ahnen DJ, Schildkraut JM, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Burt RW. BMC Cancer. 2011 Oct 4;11:424. PMID: 21970370

- Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Hansel DE, Rahman A, House M, Ashfaq R, Berg K, Yeo CJ, Maitra A. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6152-8. PMID: 15448002

- Tsuda M, Davis IJ, Argani P, Shukla N, McGill GG, Nagai M, Saito T, Lae M, Fisher DE, Ladanyi M. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007 Feb 1;67(3):919-29. PMID: 17283122

- Chen Y, Takita J, Mizuguchi M, Tanaka K, Ida K, Koh K, Igarashi T, Hanada R, Tanaka Y, Park MJ, Hayashi Y. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer. 2007 Apr;46(4):348-58. PMID: 17243166

- Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med. 2005 Jun;11(6):284-92. PMID: 15949770

- Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med. 2004 Dec;4(8):855-68. PMID: 15579033

- Rosario M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 2003 Jun;13(6):328-35. PMID: 12791299